Institut Paoli-calmettes
Clinical trials sponsored by Institut Paoli-calmettes, explained in plain language.
-
New hope for aggressive breast cancer: adding immunotherapy to standard treatment
Disease control OngoingThis study is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery helps eliminate aggressive inflammatory breast cancer tumors. It involves 52 adults with a specific type of breast cancer (HER2-negative) that has not spread. The mai…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Scientists search for hidden cancer clues in tissue samples
Knowledge-focused OngoingThis study aims to identify molecular patterns in tissue samples that might predict how gynecological cancers behave. Researchers will collect samples from 300 women with suspected ovarian, cervical, or endometrial cancer. The goal is to find connections between these molecular p…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Apr 04, 2026 03:35 UTC
-
Blood test may predict which kidney cancer drugs work best
Knowledge-focused OngoingThis study aims to determine if measuring two specific proteins (MMP2 and MMP9) in blood can help predict how well patients with metastatic kidney cancer will respond to anti-angiogenic drugs like Sunitinib or Pazopanib. Researchers will compare protein levels in 50 patients rece…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Scientists search for clues in breast cancer tumors to predict treatment success
Knowledge-focused OngoingThis study aims to understand why some patients with advanced breast cancer respond well to standard hormone therapy plus ribociclib, while others do not. Researchers will analyze tumor and blood samples from about 115 patients before and after treatment to look for genetic patte…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC